

Applicants: Mark Ledebot et al.
Application No.: 10/005,133

REMARKS

The Response

Double Patenting

The Examiner has rejected claims 1-5, 17, 20 and 21 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3, 5 and 12 of United States Patent 6,884,804 B2 (hereafter “the ‘804 patent”).

Applicants provide herewith a terminal disclaimer over the ‘804 patent, thereby obviating this rejection.

Conclusion

Applicants request that the Examiner consider applicants’ arguments and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,

/Karen E. Brown/
Karen E. Brown
Reg. No. 43,866
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6168
Fax: (617) 444-6483